コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 es compared with equal doses of conventional selegiline.
2 e dismutase and hence mimicked the action of selegiline.
3 ed the selective monoamine oxidase inhibitor selegiline (10 mg a day), alpha-tocopherol (vitamin E, 2
4 lthy men after a 28-day treatment with Zydis selegiline (2.5, 5.0, or 10 mg/day) and in 3 subjects re
6 ere randomly assigned to receive transdermal selegiline (20 mg applied once daily by means of a 20-cm
7 -tocopherol (vitamin E, 2000 IU a day), both selegiline and alpha-tocopherol, or placebo for two year
8 tidepressant activity for high doses of oral selegiline and for transdermal selegiline suggesting tha
9 on the use of the potential neuroprotectant selegiline and patients on pramipexole in the SPECT stud
10 es with monoamine oxidase type B inhibitors (selegiline and rasagiline), coenzyme Q10, creatine, and
11 cal mucosa producing higher plasma levels of selegiline and reduced amphetamine metabolites compared
12 adverse event profile of the patients given selegiline and those given placebo with the exception of
13 itiated to examine the benefits of deprenyl (selegiline) and alpha-tocopherol in slowing the progress
14 giline suggesting that when plasma levels of selegiline are elevated, brain MAO-A might also be inhib
15 though there is indirect evidence that Zydis selegiline at high doses loses its selectivity for MAO-B
18 al trials of the monoamine oxidase inhibitor selegiline for treating cocaine addiction, we required a
19 gated the efficacy and safety of transdermal selegiline in adult outpatients with major depressive di
22 rimary outcome for the patients treated with selegiline (median time, 655 days; P=0.012), alpha-tocop
25 findings clearly indicate the importance of selegiline on measured Cu,Zn-SOD and Mn-SOD activity in
26 ent from Alzheimer's disease, treatment with selegiline or alpha-tocopherol slows the progression of
27 of VH was only weakly correlated with use of selegiline (Spearman's rho 0.22, p=0.005) and ergot dopa
28 doses of oral selegiline and for transdermal selegiline suggesting that when plasma levels of selegil
29 6 weeks in patients treated with transdermal selegiline than in those given placebo according to all
30 r 10 mg/day) and in 3 subjects receiving the selegiline transdermal system (Emsam patch, 6 mg/day) us
32 AO-A inhibition in humans by formulations of selegiline, which are currently postulated but not verif
33 ) is an orally disintegrating formulation of selegiline, which is absorbed through the buccal mucosa
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。